AMBU-B Stock Analysis: Ambu | CO
Medical Devices | CO, Denmark | Market Cap: 17.569m DKK | 12M Return: -30.2% | DK0060946788 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 48.2M
EPS Trend: 72.4%
Qual. Beats: 0
Rev. Trend: 97.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ambu A/S is a Denmark-based medical technology company that researches, develops, manufactures, and markets devices across North America, Europe, and international markets. The company operates within the Health Care Equipment sub-industry and is classified as a mid-cap stock. Ambu is widely recognized as a pioneer of single-use, disposable medical devices, particularly in endoscopy, a business model that distinguishes it from competitors offering reusable alternatives and aligns with healthcare providers growing focus on infection control.
The companys product portfolio spans several clinical areas: endoscopy (bronchoscopes, video laryngoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, ureteroscopes, and displaying/processing units); neurology (EEG and EMG electrodes, EMG-guided injections, and intraoperative monitoring products); cardiology (ECG electrodes); airway management and anaesthesia (single and double lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators); and emergency care and training (extrication collars, ALS and BLS training manikins, mobile workstations, and patient monitoring and diagnostics devices). Ambu also manufactures video capture solutions for OEM customers in medical and defense imaging applications.
Founded in 1937 and headquartered in Ballerup, Denmark, Ambu serves a global customer base of hospitals, clinics, and emergency responders. The medical device sector in which it operates is subject to stringent regulatory oversight, including FDA approvals in the United States and CE marking in Europe, which shape product development cycles and market entry strategies for new devices.
- Single-use endoscope demand drives endoscopy segment growth
- Pricing competition from Olympus and Boston Scientific pressures margins
- FDA clearances for GI endoscopy portfolio expand US market access
| Net Income: 510.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 3.20 > 1.0 |
| NWC/Revenue: 31.44% < 20% (prev 32.38%; Δ -0.94% < -1%) |
| CFO/TA 0.12 > 3% & CFO 941.0m > Net Income 510.0m |
| Net Debt (-126.0m) to EBITDA (1.09b): -0.12 < 3 |
| Current Ratio: 2.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (266.6m) vs 12m ago -0.31% < -2% |
| Gross Margin: 56.04% > 18% (prev 59.94%; Δ -3.90% > 0.5%) |
| Asset Turnover: 82.22% > 50% (prev 80.56%; Δ 1.67% > 0%) |
| Interest Coverage Ratio: 9.89 > 6 (EBIT TTM 702.0m / Interest Expense TTM 71.0m) |
| A: 0.25 (Total Current Assets 3.07b - Total Current Liabilities 1.11b) / Total Assets 7.78b |
| B: 0.76 (Retained Earnings 5.89b / Total Assets 7.78b) |
| C: 0.09 (EBIT TTM 702.0m / Avg Total Assets 7.59b) |
| D: 3.84 (Book Value of Equity 6.17b / Total Liabilities 1.61b) |
| Altman-Z'' = 8.78 = AAA |
| DSRI: 1.13 (Receivables 1.05b/882.0m, Revenue 6.24b/5.96b) |
| GMI: 1.07 (GM 59.94% / 56.04%) |
| AQI: 0.96 (AQ_t 0.44 / AQ_t-1 0.46) |
| SGI: 1.05 (Revenue 6.24b / 5.96b) |
| TATA: -0.06 (NI 510.0m - CFO 941.0m) / TA 7.78b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at DKK 72.85 with a total of 650,892 shares traded. Over the past week, the price has changed by +8.17%, over one month by +10.55%, over three months by +7.53% and over the past year by -30.16%.
Current recommended Stop Loss: 67.80 (which is 6.9% or 2.3 ATR below the current price).
Ambu has no consensus analysts rating.
P/E Trailing = 35.0781
P/E Forward = 22.9885
P/S = 2.8169
P/B = 2.8567
P/EG = 2.8489
Revenue TTM = 6.24b DKK
EBIT TTM = 702.0m DKK
EBITDA TTM = 1.09b DKK
Long Term Debt = 19.0m DKK (from longTermDebt, last quarter)
Short Term Debt = 87.0m DKK (from shortTermDebt, last quarter)
Debt = 579.0m DKK (from shortLongTermDebtTotal, last quarter) (leases 560.0m already included)
Net Debt = -126.0m DKK (calculated: Debt 579.0m - CCE 705.0m)
Enterprise Value = 17.4b DKK (17.6b + Debt 579.0m - CCE 705.0m)
Interest Coverage Ratio = 9.89 (Ebit TTM 702.0m / Interest Expense TTM 71.0m)
EV/FCF = 27.13x (Enterprise Value 17.4b / FCF TTM 643.0m)
FCF Yield = 3.69% (FCF TTM 643.0m / Enterprise Value 17.4b)
FCF Margin = 10.31% (FCF TTM 643.0m / Revenue TTM 6.24b)
Net Margin = 8.18% (Net Income TTM 510.0m / Revenue TTM 6.24b)
Gross Margin = 56.04% ((Revenue TTM 6.24b - Cost of Revenue TTM 2.74b) / Revenue TTM)
Gross Margin QoQ = 59.45% (prev 60.27%)
Tobins Q-Ratio = 2.24 (Enterprise Value 17.4b / Total Assets 7.78b)
Interest Expense / Debt = 12.26% (Interest Expense 71.0m / Debt 579.0m)
Taxrate = 23.08% (153.0m / 663.0m)
NOPAT = 540.0m (EBIT 702.0m * (1 - 23.08%))
Current Ratio = 2.77 (Total Current Assets 3.07b / Total Current Liabilities 1.11b)
Debt / Equity = 0.09 (Debt 579.0m / totalStockholderEquity, last quarter 6.17b)
Debt / EBITDA = -0.12 (Net Debt -126.0m / EBITDA 1.09b)
Debt / FCF = -0.20 (Net Debt -126.0m / FCF TTM 643.0m)
Total Stockholder Equity = 6.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.72% (Net Income 510.0m / Total Assets 7.78b)
RoE = 8.38% (Net Income TTM 510.0m / Total Stockholder Equity 6.08b)
RoCE = 11.50% (EBIT 702.0m / Capital Employed (Equity 6.08b + L.T.Debt 19.0m))
RoIC = 8.38% (NOPAT 540.0m / Invested Capital 6.44b)
WACC = 8.17% (E(17.6b)/V(18.1b) * Re(8.13%) + D(579.0m)/V(18.1b) * Rd(12.26%) * (1-Tc(0.23)))
Discount Rate = 8.13% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 5.82 | Cagr: 0.04%
[DCF] Terminal Value 77.97% ; FCFF base≈535.8m ; Y1≈614.2m ; Y5≈903.9m
[DCF] Fair Price = 60.60 (EV 13.6b - Net Debt -126.0m = Equity 13.7b / Shares 226.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 72.40 | EPS CAGR: 35.86% | SUE: -0.59 | # QB: 0
Revenue Correlation: 97.57 | Revenue CAGR: 10.61% | SUE: -0.65 | # QB: 0
EPS current Quarter (2026-12-31): EPS=0.94 | Chg30d=N/A | Revisions=+0% | Analysts=1
EPS current Year (2026-09-30): EPS=2.38 | Chg30d=-0.51% | Revisions=+44% | GrowthEPS=+4.5% | GrowthRev=+6.5%
EPS next Year (2027-09-30): EPS=3.04 | Chg30d=-0.57% | Revisions=-22% | GrowthEPS=+27.4% | GrowthRev=+11.3%
[Analyst] Revisions Ratio: +13% (up=7, down=5)